Covid-19 showed that pharma companies can be nimble and implement changes that prevent processes from weighing down on operations. But which of these operational and strategic changes will stand the test of time and make this year and the future bright for the industry?
The three-year-old digital health startup began trading on the New York Stock Exchange on Thursday. It merged with a subsidiary of Oaktree Capital Management in a deal that valued the company at $1.6 billion.
The Bay Area hearing device-maker planned to raise $141.3 million in an upsized IPO. Its stock started trading on Nasdaq under the ticker “EAR.”
The direct-to-consumer telehealth startup will go public through a merger with special purpose acquisition company Oaktree Acquisition Corp. The combined entity is expected to be valued at $1.6 billion.
Plume provides access to telehealth consultations for patients seeking gender-affirming hormone therapy. Recently, the startup began partnering with employers to offer its services as a benefit.
Thirty Madison, which owns direct-to-consumer pharmacy brands for hair loss, migraines and acid reflux, raised $47 million in a series B round. Polaris Partners led the round, and Johnson & Johnson participated as an investor.